Publications

Publications

At Bayer, we are working in collaboration with the leading scientific, academic, and community partners to improve our understanding of cardiorenal diseases.  

 

We invite you to explore Bayer-supported publications pertaining to heart failure with a focus on LVEF ≥ 40%. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

 

To help narrow down your search, choose the relevant tags and click apply. Applying multiple tags will narrow your results.

 

Last updated “June 17, 2025”.

Types of Enhancements Available

audio
Audio
infographic
Graphical Abstract
PLS
Plain Language Summary
video
Video
other
Others

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 55    

Filtered results: 55

Albuminuria as a diagnostic criterion and a therapeutic target in heart failure and other cardiovascular disease

Bozkurt B et al., Eur J Heart Fail. 2025.

https://onlinelibrary.wiley.com/doi/10.1002/ejhf.3683, 01 05 2025

Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial

Cunningham JW et al. Eur J Heart Fail. 2025.

Cunningham JW, 01 05 2025

Effects of finerenone on readmissions for heart failure: Insights from the FINEARTS-HF trial

Bhatt AS et al. Journal of Cardiac Failure. 2025.

Bhatt AS, 01 05 2025

Finerenone in heart failure with improved ejection fraction: The FINEARTS-HF randomized clinical trial

Pabon MA et al. JAMA Cardiol. 2025.

Pabon MA, 01 05 2025

Finerenone: Potential clinical application across the spectrum of cardiovascular disease and chronic kidney disease

Haq N et al., J. Clin. Med. 2025.

Haq N, 01 05 2025

The role of finerenone in the concomitant management of chronic kidney disease-type 2 diabetes and the implication for heart failure prevention and treatment

Taub PR et al., Heart Fail Rev. 2025.

Taub PR, 01 05 2025

Use of finerenone in patients with chronic kidney disease at high risk of heart failure

Hakim JP et al., Metabolism. 2025.

Hakim JP, 01 05 2025

Finerenone across the spectrum of kidney risk in heart failure: The FINEARTS-HF trial

Ostrominski JW et al. J Am Coll Cardiol HF. 2025.

Ostrominski JW, 01 04 2025

Finerenone and New York Heart Association functional class in heart failure: The FINEARTS-HF trial

Ostrominski JW et al. J Am Coll Cardiol HF. 2025.

Ostominski JW, 01 04 2025

Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial

Butt JH et al. European Journal of Heart Failure. 2025.

Butt, JH, 01 04 2025